These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35993970)

  • 1. Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe.
    Mancuso ME; Castaman G; Pochopien M; Aballéa S; Drzewiecka A; Hakimi Z; Nazir J; Fatoye F
    J Med Econ; 2022; 25(1):1068-1075. PubMed ID: 35993970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
    Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.
    Kragh N; Tytula A; Pochopien M; Aballéa S; Toumi M; Hakimi Z; Nazir J; Bystrická L; Fatoye F
    Eur J Haematol; 2023 Mar; 110(3):262-270. PubMed ID: 36398467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors.
    Cafuir L; Estrin A; Chen E; Hinds D; Prince P; Thorburn J; Mead H; Kempton CL
    J Med Econ; 2022; 25(1):984-992. PubMed ID: 35848992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The societal burden of haemophilia A. III - The potential impact of emicizumab on costs of haemophilia A in Australia.
    Brown LJ; La HA; Li J; Brunner M; Snoke M; Kerr AM
    Haemophilia; 2020 Aug; 26 Suppl 5():21-29. PubMed ID: 32935399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru.
    Bitrán R; Peña C; Arpón P; Loayza N; Salas K; Del Villar C; Chumpitaz G; Salinas V
    Medwave; 2022 Mar; 22(2):e8703. PubMed ID: 35323824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
    Le Quellec S
    Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors.
    Watanabe AH; Lee SWH; Chai-Adisaksopha C; Lim MY; Chaiyakunapruk N
    Value Health Reg Issues; 2022 Mar; 28():7-13. PubMed ID: 34800834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy.
    Di Brino E; Yan S; Tomic R; Panebianco M; Dlotko E; Stern L; Basile M; Rumi F; Cicchetti A; Marino R
    J Med Econ; 2023; 26(1):554-564. PubMed ID: 37039544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada.
    Yu JK; Wong WWL; Keepanasseril A; Iorio A; Edginton AN
    Haemophilia; 2023 Mar; 29(2):488-497. PubMed ID: 36528890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.
    Klamroth R; Wojciechowski P; Aballéa S; Diamand F; Hakimi Z; Nazir J; Abad-Franch L; Lethagen S; Santagostino E; Tarantino MD
    J Blood Med; 2021; 12():115-122. PubMed ID: 33664606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A.
    Sun SX; Frick A; Balasa V; Roberts JC
    Expert Rev Hematol; 2022 Oct; 15(10):943-950. PubMed ID: 36000620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
    Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC
    Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677
    [No Abstract]   [Full Text] [Related]  

  • 19. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
    Díaz-Ricart M; Isola IM; Escolar G
    Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors.
    Escobar M; Agrawal N; Chatterjee S; Bhattacharya S; Caicedo J; Bullano M; Schultz BG
    J Med Econ; 2023; 26(1):574-580. PubMed ID: 36989380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.